168. EIAV-based vectors for the treatment of haemophilia A

Effective gene therapy for haemophilia necessitates a vector system that is not subject to a pre-existing immune response, has adequate coding capacity, can transduce non-dividing cells at a relevant site and gives long-term expression. Lentiviral-based vector systems are currently the only integrating vector systems that fulfil these criteria for the delivery of Factor VIII. Oxford BioMedica's lentiviral vector system is based on the non-primate lentivirus, Equine Infectious Anaemia Virus (EIAV).